Industry veteran with expertise in oncology
and immuno-oncology and a strong track record of advancing
programs through clinical development
PHILADELPHIA, May 2, 2024
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma"
or the "Company"), a clinical-stage biopharmaceutical company
focused on discovering and developing innovative immunotherapies,
today announced the appointment of Eugene
P. Kennedy, M.D., F.A.C.S. as the Company's Chief Medical
Officer. Dr. Kennedy brings over 15 years of clinical and industry
experience, including cross-functional leadership driving clinical
development and regulatory strategies for oncology and
immuno-oncology focused organizations. In the role of Chief Medical
Officer, Dr. Kennedy will be responsible for overseeing Carisma's
clinical development, regulatory and medical affairs functions.
"On behalf of Carisma, I am delighted to welcome Gene to our
team," said Steven Kelly, President
and Chief Executive Officer of Carisma. "With his extensive
expertise in oncology and a proven track record in designing and
executing clinical trials for solid tumors, Dr. Kennedy brings
invaluable insights to our organization that should immediately
have a positive impact. We are excited to add his leadership to our
organization to build on the momentum in our clinical program and
to help advance our pipeline to deliver innovative treatments to
patients."
"I am excited to join Carisma, a company at the forefront of
developing engineered macrophages across various therapeutic
areas," said Dr. Kennedy. "It is an exciting time for Carisma as it
progresses its anti-HER2 program through clinical development.
Throughout my career, I have always been driven to seek out new
modalities with the potential to profoundly impact patients' lives,
and Carisma represents an extraordinary opportunity for me to
fulfill this mission."
Before joining Carisma, Dr. Kennedy served as Chief Medical
Officer at Galera Therapeutics, where he oversaw the development of
the company's radiotherapy in cancer. Prior to his time at Galera,
Dr. Kennedy served as Chief Medical Officer at Innovative Cellular
Therapeutics, where he played a pivotal role in developing the
Phase 1 clinical protocol and securing a first-in-human IND for a
solid tumor CAR T-cell therapy. Previously, he served as Chief
Medical Officer at Lumos Pharma, where he was responsible for
clinical development strategy and execution, alongside investor and
patient engagement efforts. Before Lumos, Dr. Kennedy held the
role of Chief Medical Officer at NewLink Genetics, overseeing
clinical trials across multiple product candidates and indications.
Prior to joining NewLink Genetics, he served as Associate Professor
of Surgery at Thomas Jefferson
University and held leadership positions as Chief of the
Section of Pancreatic and Hepatobiliary Surgery and Co-Director of
the Jefferson Pancreas, Biliary & Related Cancers Center. Dr.
Kennedy also has practiced, taught, and held leadership roles at
the Johns Hopkins Hospital and Louisiana State
University. Dr. Kennedy received a bachelor's degree from
the University of Virginia and an M.D.
from the Medical College of
Virginia.
About Carisma
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical
company focused on utilizing our proprietary macrophage and
monocyte cell engineering platform to develop transformative
immunotherapies to treat cancer and other serious diseases. We have
created a comprehensive, differentiated proprietary cell therapy
platform focused on engineered macrophages and monocytes, cells
that play a crucial role in both the innate and adaptive immune
response. Carisma is headquartered in Philadelphia, PA. For more information, please
visit www.carismatx.com.
Investors:
Shveta
Dighe
Head of Investor Relations
investors@carismatx.com
Media Contact:
Julia
Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-appoints-dr-eugene-p-kennedy-as-chief-medical-officer-302133840.html
SOURCE Carisma Therapeutics Inc.